So with that, I'll turn the call over to Rob.

Thank you, Liz.

Good morning, everyone, and thank you for joining us.

AVI delivered another excellent quarter, with results once again exceeding our expectations.

I'm especially pleased with the execution across our business, including double-digit sales growth from our diverse portfolio, the advancement of our compelling pipeline of innovative medicines, and our planned acquisition of Apogee Therapeutics, which represents an exciting opportunity to bolster Abbey's leading immunology portfolio.

Turning to our second quarter performance, We achieved adjusted earnings per share of $3.65, which is $0.06 above our guidance midpoint.

Total net revenues were nearly $17 billion, beating our expectations by $300 million and reflecting robust sales growth of 10.2%.

But nonetheless, our ability to start to communicate and basically highlight this innovation is will come here in the fourth quarter.